10th International Conference on Complement Therapeutics

Preliminary Program

Saturday, June 24

     

6:00 PM

 

Conference Registration

     

8:00 PM

 

Welcome Reception and Dinner

     

Sunday, June 25

     

8:00 AM

 

Breakfast

     

SESSION I

 

Neurological, Ocular & Lysosomal Storage Diseases

Chairs: Kip Connor and Andrea Tenner

9:00 AM

1

How complement eliminates synapses in development and disease

Beth Stevens

9:20 AM

2

Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss

Andrea Tenner and Michael Hernandez

9:40 AM

3

Targeting the lectin complement pathway in brain disorders

Maria-Grazia De Simoni

10:00 AM

4

Neuroprotective role of complement inhibition in retinal degeneration

Kip Connor

10:20 AM

5

Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease

Joerg Koehl, Manoj Pandey, Thomas Burrow, Reena Rani, Lisa Martin, David Witte, Kenneth Setchell, Mary McKay, Albert Magnusen, Wujuan  Zhang, Benjamin Liou, and Gregory Grabowski

     
   

Beyond Discovery I

10:40 AM

6

How will BREXIT and the new Unitary Patent System affect patents in Europe?

Janet Reed

     

10:55 AM

 

Coffee Break & Poster Viewing

     

SESSION II

 

Complement in Cancer Progression & Therapy

Chairs: Edimara Reis and Ronald Taylor

11:40 AM

7

Complement and humoral innate immunity in the regulation of cancer-related inflammation

Alberto Mantovani

12:00 PM

8

Complement in cancer: untangling an intricate relationship

Edimara Reis

12:20 PM

9

Looking at cell surface expressed C1q through a different prism: a potential target for cancer therapy?

Berhane Ghebrehiwet, Evelyn Kandov, Daniel Irizarry, Uday Kishore, and Ellinor Peerschke

12:40 PM

10

Premetastatic pneumonia. Unrecognized disease - a new target for anticancer therapy

Maciej Markiewski and Magdalena Karbowniczek

1:00 PM

11

Compelling evidence for re-design of dosing schedules in mAb-based immunotherapy of cancer:  Lessons learned from CD20 mAbs

Ronald Taylor and Margaret Lindorfer

1:20 PM

12

Complement-fed immune stimulatory vicious cycle: a safety issue in nano-bio-pharmacotherapy

Janos Szebeni

     

1:40 PM

 

Lunch and Informal Discussions

     

7:30 PM

 

Dinner and Informal Discussions

     
             

Monday, June 26

     

8:00 AM

 

Breakfast

     

SESSION III

 

Targerting Diseases at the Terminal Pathway Level

Chairs: Joerg Koehl and Christoph Schmidt

9:00 AM

13

C5 inhibition: News about eculizumab for refractory generalized Myasthenia Gravis (gMG) and ALXN1210

Camille Bedrosian and on behalf of the Alexion refractory gMG and ALXN1210 teams and participating investigators and patients

9:20 AM

14

Mechanistic insight into C5 activation reveals limitations of therapeutic C5 inhibitors and illustrates how those can be overcome

Christoph Schmidt and Markus Harder

9:40 AM

15

Role of complement membrane attack complex in sepsis

Peter Ward, Fatemeh Fattahi, Firas Zetoune, Wenchao Song, B. Paul Morgan, and Michael Matthay

10:00 AM

16

Mechanistic insights into terminal pathway activation in osteoarthritis

Jo Bramhall, Christina Bessant, Isabelle Osuch, Amy  Dawson, Karen Miller, Kathy Triantafilou, and Eva-Maria Nichols

10:15 AM

17

C5aR1 as a target to suppress the development and pathogenicity of autoantibodies in experimental epidermolysis bullosa acquisita

Christian Karsten, Kristin  Schröder, Ania Kordowski, Balint  Kovacs, Ralf Ludwig, and Jörg Köhl

     
   

Beyond Discovery II

10:30 AM

18

Funding Translational Research and Development of Pharmaceutical Innovation - Sources and Strategies to Create Novel Therapeutics

Charles Baltic III

     

10:50 AM

 

Coffee Break & Poster Viewing

     

SESSION IV

 

Molecular, Physiological & Pathophysiological Mechanisms

Chairs: Piet Gros and Lubka Roumenina

11:30 AM

19

Structural insights into complement activation and regulation

Piet Gros

11:50 AM

20

“The C3 tickover” studied with S77, an antibody that inhibits it

Peter Lachmann, Elizabeth Lay, David Seilly, and Menno Van Lookeren Campagne

12:10 PM

21

Hemolysis drives particular susceptibility of glomerular endothelium to complement overactivation.

Olivia May, Nicolas Merle, Anne Grunenwald, Helena Rajaratnam, Samantha Knockaert, Jordan Dimitrov, Veronique Fremeaux-Bacchi, Marie Frimat, and Lubka Roumenina

12:30 PM

22

Orphan complement activation fragment C4a as a novel untethered agonist mediates effector functions through binding to protease-activated receptor (PAR) 1 and 4

Hongbin Wang, Daniel Ricklin, and John Lambris

12:45 PM

23

Functional characterization of alternative pathway C3 and C5 convertase inhibitors

Ronald Gorham Jr., Seline Zwarthoff, Xiaoguang Xue, Maartje Ruyken, Mihály Józsi, Piet Gros, and Suzan Rooijakkers

1:00 PM

24

Carboxypeptidase N and Procarboxypeptidase B2 play complementary and non-redundant roles in the protection against anaphylatoxins and inflammatory mediators

Lawrence Leung and John Morser

1:20 PM

25

Functional and structural insights into properdin control of the complement alternative pathway

Dennis Pedersen, Lubka Roumenina, Rasmus Jensen, Trine Gadeberg, Chiara Marinozzi, Capucine Picard, Tania  Rybkine, Steffen Thiel, Uffe Sørensen, Cordula  Stover, Veronique  Fremeaux‐Bacchi, and Gregers Andersen

     

1:35 PM

 

Lunch and Informal Discussions

     

7:30 PM

 

Dinner and Informal Discussions

     
         

Tuesday, June 27

     

8:00 AM

 

Breakfast

     

SESSION V

 

Kidney Diseases, I/R Injury & Transplantation

Chairs: Charles Baltic and Alireza Biglarnia

9:00 AM

26

Precision medicine for C3 Glomerulopathy

Richard Smith

9:20 AM

27

C3 and C5 nephritic factors in C3 Glomerulopathies

Veronique Fremeaux-Bacchi

9:40 AM

28

The mystery of “Glomerulonephritis with dominant C3 deposition”

Carla Nester

10:00 AM

29

Alternative pathway or alternative view on renal ischemia reperfusion injury

Cees van Kooten

10:20 AM

30

Efficacy and safety of Cp40 to reduce ischemia reperfusion injury in non-human primates

Alireza Biglarnia, Frank Zoerner, Edimara Reis, Daniel Ricklin, Ranillo Resuello, Joel Tuplano, Bo  Nilsson, Martijn van Griensven, Markus Huber-Lang, and John Lambris

10:40 AM

31

Protection against thromboinflammation in kidney transplantation using a PEG-phospholipid construct

Bo Nilsson

11:00 AM

32

TBA

Robert Montgomery

     

11:20 AM

 

Coffee Break & Poster Viewing

     

SESSION VI

 

Targerting Diseases at the Initiation/Amplification Level

Chairs: Daniel Ricklin and Carl Atkinson

11:40 AM

33

Compstatin Cp40 (AMY-101): a C3-targeted complement inhibitor reaching its prime for bedside intervention

John D Lambris, Edimara Reis, Daniel Ricklin, Nadja Berger, Tchilabalo Alayi, Georgia Sfyroera, Hongbin Wang, Markus Huber-Lang,Bo Nilsson, Kristina Nilsson-Ekdahl, Richard J Smith, Carla Nester, Meryl Waldman, Dimitrios Mastellos, Margaret A Lindorfer, Ronald P Taylor, Piet Gros, George Hajishengallis, Lorraine M Rusch, Elias Sayias, Margarita Nunez, Despina Yancopoulou, and Antonio M Risitano

12:00 PM

34

Complement and periodontitis: the role of the alternative pathway

George Hajishengallis, Xiaofei Li, Tetsuhiro Kajikawa, Evlambia Hajishengallis, Edimara Reis, and John Lambris

12:20 PM

35

Interconnections and key roles of alternative and lectin pathway components in the pathogenesis of experimental rheumatoid arthritis

Nirmal Banda, Robert Scheinman, Wuding Zhou, Conrad Farrar, Steven Sacks, Steffen Thiel, Yuichi Endo, Teijo Fujita, Hideharu Sekine, and Michael Holers

12:40 PM

36

Role of complement activation in hemorrhagic shock – protection by C3 Blockade

Markus Huber-Lang, Ranillo Resuello, Joel Tuplano, Sofia Koutsogiannaki, Alexandra Primikyri, Edimara Reis, Kristina Nilsson, Bo Nilsson, Daniel Ricklin, John  Lambris, and Martijn  van Griensven

1:00 PM

37

Systemic- and local complement activation controls the NLRP3 inflammasome pathway in patients with atherosclerosis

Nathalie Niyonzima, Siril Bakke, Bente Halvorsen, Ida Gregersen, Mona Skjelland, Arne Yndestad, Øystein Sandanger, Geir Andersen, Lars Gullestad, Eicke Latz, Pål Aukrust, Tom Mollnes, and Terje Espevik

1:20 PM

38

Inhibitors of the alternative complement may have lower infection risks than anti-C5 treatments

Anna Schubart

     

1:35 PM

 

Lunch and Informal Discussions

     

3:00 PM

 

City Tour

     

7:30 PM

 

Dinner and Informal Discussions

     

Wednesday, June 28

8:00 AM

 

Breakfast

SESSION VII

 

Hemolytic & Pulmonary Diseases

Chairs: Antonio Risitano and Sacha Zeerleder

9:00 AM

39

Progresses in clinical development of novel complement inhibitors for PNH: Question (and answers?)

Antonio Risitano

9:20 AM

40

Targeting complement to treat paroxysmal nocturnal hemoglobinuria (PNH)

Rodrigo Calado

9:40 AM

41

Intra and extra vascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH): a never-ending hike between beds and benches

Rosario Notaro

10:00 AM

42

The effect of complement inhibition on erythrocyte destruction in AIHA

I Baas, Edimara Reis, John Lambris, M de Haas, D Wouters, and Sasha Zeerleder

10:20 AM

43

Complement therapeutics in cigarette smoke induced emphysema development and progression

Sarah Stephenson, Ali Alawieh, Andrew Kirst, Stephen Tomlinson, and Carl Atkinson

10:40 AM

44

Cigarette smoke impairs complement-mediated phagocytosis of Streptococcus pneumoniae in patients with chronic obstructive pulmonary disease allowing persistent infection in the respiratory tract

Leire Aguinagalde, Carmen Ardanuy, Josefina Liñares, Ernesto García, and Jose Yuste

10:55 AM

45

Complement inhibition in brain dead donors mitigates post-lung transplantation inflammation and injury in a murine model

Kunal Patel, Qi Cheng, Biao Lei, Daniel Allen, Timothy Whelan, Martin Goddard, Stephen Tomlinson, Satish Nadig, and Carl Atkinson

     

11:10 AM

 

Coffee Break & Poster Viewing

     
   

Beyond Discovery III

11:50 AM

46

The University Center for Innovation Model

John Swartley

     

SESSION VIII

 

Diagnostics & Biomarkers

Chairs: Anna Blom and Tom Mollnes

12:10 PM

47

Complement analyses: new concepts in the era of complement inhibitory therapy in the clinic

Tom Mollnes

12:30 PM

48

Optimization of complement functional assays for the testing of complement inhibitory therapeutics

Ashley Frazer-Abel, Thuy Ton, Delphine El Mehdi, Carolina Vega, and Pascal Deschatelets

12:45 PM

49

Novel assay for measurement of plasma C4d levels

Marcin Okroj, Myriam Martin, Daniel Ajona, Anders Bengtsson, Ruben Pio, and Anna Blom

1:05 PM

50

Further studies on C1q as a biomarker of disease activity in SLE

Kristina Ekdahl

1:20 PM

51

Proteomic analysis of gingival crevicular fluid from non-human primates locally treated with the complement inhibitor Cp40           

Nagihan Bostanci, Kai Bao, Li Li Xiaofei, Tomoki Maekawa, Jonas Grossmann, George Belibasakis, John Lambris, and George Hajishengallis

1:35 PM

52

Simultaneous monitoring of multiple complement activation markers: development of rapid, point-of-care assays for sC5b9 and C4d and proof of concept in the hemodialysis clinic setting

Nick Staten, W Schaiff, Adrienne Clagettt, Jacklyn Kesler, Junhan Wang, Jennifer Ritchie, Ashley Anderson, Brigitta Brannon, Charles Ellis, Talat Ikizler, and Martin Schmidt

     

1:50 PM

 

Lunch and Informal Discussions

     

8:00 PM

 

Farewell Dinner

     

Thursday, June 29

     

8:00 AM

 

Breakfast

 
     
   

Departure

 
           

POSTERS

53

Complement and periodontitis: the role of the classical pathway

Tetsuhiro Kajikawa, Edimara Reis, John Lambris, and George Hajishengallis

54

Intracellular complement activation involves in liver damage of Trichloroethylene-sensitized BALB/c mice

Yun Yu, Xiao-Dong Yang, Jia-Xiang Zhang, Tong Shen, and Qixing Zhu

55

Poly(I:C) aggravates immunological liver injury in mouse model of trichloroethylene sensitization

Tong Shen, Cheng Zhang, Jia-Xiang zhang, and Qixing Zhu

56

Roles for the N-terminal, C-terminal and Y402H polymorphism of CFH in an experimental model for neovascular age-related macular degeneration: differential effects on complement, inflammation and oxidative stress

Céline Borras, Kimberley Delaunay, Sylvie Jorieux, Toufik Abache, Marie-Christine Naud, Alexandre Sellam, Mohamed El Sanharawi, NA AN, Emmanuelle Gelizé, Patricia Lassiaz, Francine Bahar-Cohen, Frederic Mascarelli, and Virginie Dinet

57

 Humanised mouse properdin could augment the alternative pathway of wild type mouse and normal human sera on zymosan and Plasmodium falciparum merozoites coated plate.

Mohenned Alsaadawi and Nicholas Lynch

58

The relationship between Eculizumab concentration, Eculizumab-C5 complexes, C5 concentration and complement hemolytic activity

Maarten Oranje, Diana Wouters, Frederike Bemelman, and Kyra Gelderman

59

Complement therapeutics for prevention of PF4/heparin antibodies

Sanjay Khandelwal and Gowthami Arepally

60

Delineation of mechanisms for evasion of complement deposition by Burkholderia pseudomallei

Laura Stansbury, Minal Mulye, Michael Woodman, and R. Wooten

61

In vitro testing as an effective way to evaluate therapeutics for complement inhibition or activation

Jaclyn Dennis, Carter Reid, Erin Archuleta, Matthew Eggleston, Dana Le, Roza Mkonu, Linda Remigio, and Vijaya Knight

62

Evaluation of mechanisms of paroxysm in paroxysmal nocturnal hemoglobinuria: “Bystander Hemolysis” vs. perturbation of soluble regulators

Mingjun Huang, Jane Thanassi, Manuel Galvan, Guangwei  Yang, Xuan  Yuan, Yongsen  Zhao, Dharaben  Patel, Joanne Fabrycki, Amanda Luu, Wengang  Yang, Steven  Podos, Joel  Barrish, and Robert  Brodsky

63

Repression of C1QBP is a prerequisite of pathologic cardiac hypertrophy

Eman Hagag, Božena Kesić, and Peter Mirtschink

64

A rapid assay for the determination of ADAMTS-13 activity

Nikolaus Binder, Margaret Griffiths, Helga Vetr, Kyle Zingaro, Patricia Bento, and Susan Faas

65

Generation of CD46, CD55 and CD59 CRISPR/Cas9 knockout cell lines

Darren Gormley, Katie West, Tara Busiau, Lisa Spatt, Richard Priest, Karen Miller, and Eva-Maria Nichols

66

Development of iC3b and full length factor B immunoassays

Christina Bessant, Darren Gormley, Marta Biedzka-Sarek, Karen Miller, and Eva-Maria Nichols

67

Genetic landscape of aHUS – a comprehensive analysis of genetic variants reported in literature

Rui-Ru Ji, Tatiana Serebriyskaya, and Natalia Kuzkina